IDiyas

For the Inventor, By the Inventor

Bedminster, NJ, United States of America

Yinfa Yan

USPTO Granted Patents = 11 

 

Average Co-Inventor Count = 3.9

ph-index = 4

Forward Citations = 105(Granted Patents)


Location History:

  • Bedminister, NJ (US) (2010)
  • Bedminster, NJ (US) (2007 - 2022)

Company Filing History:

goldMedal8 out of 1,309 
 
Wyeth
 patents
silverMedal3 out of 159 
 
Jiangsu Hengrui Medicine Company Ltd.
 patents
bronzeMedal2 out of 100 
 
Shanghai Hengrui Pharmaceutical Co., Ltd.
 patents
where one patent can have more than one assignee

Years Active: 2007-2025

Loading Chart...
Loading Chart...
11 patents (USPTO):
1. 12187684 - Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical use thereof (2025-01-07),
2. 11512055 - Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical uses thereof (2022-11-29),
3. 10144737 - Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors (2018-12-04),
4. 7705030 - Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for β-secretase modulation (2010-04-27),
5. 7700602 - Amino-5,5-diphenylimidazolone derivatives for the inhibition of β-secretase (2010-04-20),
6. 7576087 - Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands (2009-08-18),
7. 7560470 - Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands (2009-07-14),
8. 7482349 - Amino-5,5-diphenylimidazolone derivatives for the inhibition of β-secretase (2009-01-27),
9. 7417047 - Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for β-secretase modulation (2008-08-26),
10. 7259165 - Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands (2007-08-21),
11. 7238696 - Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands (2007-07-03),

Title: The Innovative Contributions of Yinfa Yan

Introduction

Yinfa Yan is a prominent inventor based in Bedminster, NJ (US), known for his significant contributions to the field of pharmaceuticals. With a total of 11 patents to his name, he has made remarkable advancements in the development of therapeutic agents.

Latest Patents

Among his latest patents are the benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ). These inventions focus on compounds that act as inhibitors of the RORγ protein, which are crucial for treating RORγ-mediated diseases or disorders. The patents detail pharmaceutical compositions containing these compounds, their preparation methods, and their therapeutic applications.

Career Highlights

Yinfa Yan has had a distinguished career, working with notable companies such as Wyeth and Jiangsu Hengrui Medicine Company Ltd. His work has significantly impacted the pharmaceutical industry, particularly in the development of innovative treatments.

Collaborations

Throughout his career, Yinfa has collaborated with esteemed colleagues, including Ronald Charles Bernotas and Michael Sotirios Malamas. These partnerships have fostered a collaborative environment that has led to groundbreaking advancements in their respective fields.

Conclusion

Yinfa Yan's contributions to the pharmaceutical industry through his innovative patents and collaborations highlight his role as a leading inventor. His work continues to influence the development of new therapeutic agents, showcasing the importance of innovation in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…